Nab-paclitaxel is a chemotherapeutic drug used to treat various solid malignant tumors. It was conceived with a solvent free formulation to overcome toxicity events and hypersensitivity reactions associated with paclitaxel. However, it still carries ocular adverse effects. The present review examines nab-paclitaxel related cystoid macular edema (CME) and the available therapeutic options.
Nab-Paclitaxel related cystoid macular edema / Di Pippo, M; Di Staso, F; De Ponte, C; Fragiotta, S; Abdolrahimzadeh, S. - In: LA CLINICA TERAPEUTICA. - ISSN 1972-6007. - 173:4(2022), pp. 377-383. [10.7417/CT.2022.2449]
Nab-Paclitaxel related cystoid macular edema
Di Pippo, M
;Di Staso, F;De Ponte, C;Fragiotta, S;Abdolrahimzadeh, S
2022
Abstract
Nab-paclitaxel is a chemotherapeutic drug used to treat various solid malignant tumors. It was conceived with a solvent free formulation to overcome toxicity events and hypersensitivity reactions associated with paclitaxel. However, it still carries ocular adverse effects. The present review examines nab-paclitaxel related cystoid macular edema (CME) and the available therapeutic options.File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
DiPippo_Nab-Paclitaxel-related-cystoid_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Dimensione
2.34 MB
Formato
Adobe PDF
|
2.34 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
